Edition:
United Kingdom

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

50.55USD
18 Jan 2018
Change (% chg)

$-0.98 (-1.90%)
Prev Close
$51.53
Open
$52.00
Day's High
$52.00
Day's Low
$50.47
Volume
200,363
Avg. Vol
262,690
52-wk High
$91.75
52-wk Low
$41.06

Select another date:

Fri, Jan 12 2018

Photo

Spark's price for Luxturna blindness gene therapy too high: ICER

The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

UPDATE 1-Spark's price for Luxturna blindness gene therapy too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

CORRECTED-Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High

* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH

Spark to charge $850,000 per patient for blindness gene therapy

Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

UPDATE 2-Spark to charge $850,000 per patient for blindness gene therapy

Jan 3 Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

Spark Therapeutics' vision-loss gene therapy to cost $850,000 per patient

Jan 3 Spark Therapeutics Inc said on Wednesday it would charge $850,000 per patient for its gene therapy to treat a rare form of blindness, lesser than analysts' expectation of around $1 million.

BRIEF-Spark Therapeutics Announces Programs To Improve Patient Access To LUXTURNA

* SPARK THERAPEUTICS ANNOUNCES FIRST-OF-THEIR-KIND PROGRAMS TO IMPROVE PATIENT ACCESS TO LUXTURNA™ (VORETIGENE NEPARVOVEC-RZYL), A ONE-TIME GENE THERAPY TREATMENT

BRIEF-Spark Therapeutics - On Jan 3, 2018, Co Announced Wholesale Acquisition Cost For Luxturna Is $425,000/Dose

* SPARK THERAPEUTICS - ON JAN 3, 2018, CO ANNOUNCED WHOLESALE ACQUISITION COST FOR LUXTURNA (VORETIGENE NEPARVOVEC-RZYL) IS $425,000/DOSE OR PER EYE Source text: (http://bit.ly/2CxDOZr) Further company coverage:

U.S. approves first gene therapy for inherited disease

The U.S. Food and Drug Administration on Tuesday approved Spark Therapeutics Inc's treatment for a rare form of blindness, marking the first time the agency has approved a gene therapy for an inherited disease.

Select another date: